MY183769A - Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl-2-oxo-1,2-dihydropyridine-3-carboxamide - Google Patents
Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl-2-oxo-1,2-dihydropyridine-3-carboxamideInfo
- Publication number
- MY183769A MY183769A MYPI2012004708A MYPI2012004708A MY183769A MY 183769 A MY183769 A MY 183769A MY PI2012004708 A MYPI2012004708 A MY PI2012004708A MY PI2012004708 A MYPI2012004708 A MY PI2012004708A MY 183769 A MY183769 A MY 183769A
- Authority
- MY
- Malaysia
- Prior art keywords
- fluorophenyl
- chloropyridin
- dihydropyridine
- yloxy
- carboxamide
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- VNBRGSXVFBYQNN-UHFFFAOYSA-N N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-3-pyridinecarboxamide Chemical compound O=C1C(C(=O)NC=2C=C(F)C(OC=3C(=C(N)N=CC=3)Cl)=CC=2)=C(OCC)C=CN1C1=CC=C(F)C=C1 VNBRGSXVFBYQNN-UHFFFAOYSA-N 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32971010P | 2010-04-30 | 2010-04-30 | |
| PCT/US2011/034417 WO2011137274A1 (en) | 2010-04-30 | 2011-04-29 | Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY183769A true MY183769A (en) | 2021-03-12 |
Family
ID=44209564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2012004708A MY183769A (en) | 2010-04-30 | 2011-04-29 | Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl-2-oxo-1,2-dihydropyridine-3-carboxamide |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8911785B2 (enExample) |
| EP (1) | EP2563763B1 (enExample) |
| JP (1) | JP5820874B2 (enExample) |
| KR (1) | KR101897302B1 (enExample) |
| CN (1) | CN102971296B (enExample) |
| DK (1) | DK2563763T3 (enExample) |
| ES (1) | ES2533075T3 (enExample) |
| HR (1) | HRP20150105T1 (enExample) |
| MY (1) | MY183769A (enExample) |
| PH (1) | PH12012502019A1 (enExample) |
| PL (1) | PL2563763T3 (enExample) |
| PT (1) | PT2563763E (enExample) |
| RS (1) | RS53790B1 (enExample) |
| SG (1) | SG184891A1 (enExample) |
| SI (1) | SI2563763T1 (enExample) |
| SM (1) | SMT201500069B (enExample) |
| WO (1) | WO2011137274A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013096858A1 (en) | 2011-12-22 | 2013-06-27 | Life Technologies Corporation | Cell culture media and methods |
| KR101545268B1 (ko) | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
| WO2016126012A1 (en) * | 2015-02-05 | 2016-08-11 | Boryung Pharmaceutical Co., Ltd | Tablet and method of preparing the same |
| EP3911320A4 (en) * | 2019-01-15 | 2022-11-30 | The Translational Genomics Research Institute | PHOSPHONATE CONJUGATES AND THEIR USES |
| US20230257364A1 (en) * | 2022-02-16 | 2023-08-17 | Cmg Pharmaceutical Co., Ltd. | Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| CN1230883A (zh) * | 1996-09-24 | 1999-10-06 | 伊莱利利公司 | 包衣颗粒制剂 |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US20100016378A1 (en) * | 2005-04-28 | 2010-01-21 | Toshio Suzuki | Method of preventing dihydropyridine compound from degradation |
| TR200504775A1 (tr) | 2005-11-30 | 2007-10-22 | Esen Beki̇r | Kendinden metal takviyeli pvc pencere ve kapı profilleri |
| DE602006004694D1 (de) * | 2006-01-05 | 2009-02-26 | Teva Pharma | Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen |
| WO2008058229A1 (en) * | 2006-11-08 | 2008-05-15 | Bristol-Myers Squibb Company | Pyridinone compounds |
| US20080260837A1 (en) * | 2007-04-20 | 2008-10-23 | Qpharma, L.L.C. | Physically stable aqueous suspensions of active pharmaceuticals |
| US8263652B2 (en) * | 2007-10-31 | 2012-09-11 | Sk Biopharmaceuticals Co., Ltd. | Stabilized pediatric suspension of carisbamate |
| JP5693239B2 (ja) | 2008-01-23 | 2015-04-01 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ４−ピリジノン化合物および癌についてのその使用 |
-
2011
- 2011-04-29 CN CN201180032341.1A patent/CN102971296B/zh active Active
- 2011-04-29 KR KR1020127031220A patent/KR101897302B1/ko active Active
- 2011-04-29 US US13/643,561 patent/US8911785B2/en active Active
- 2011-04-29 EP EP11717917.6A patent/EP2563763B1/en active Active
- 2011-04-29 PL PL11717917T patent/PL2563763T3/pl unknown
- 2011-04-29 HR HRP20150105AT patent/HRP20150105T1/hr unknown
- 2011-04-29 WO PCT/US2011/034417 patent/WO2011137274A1/en not_active Ceased
- 2011-04-29 RS RS20150055A patent/RS53790B1/sr unknown
- 2011-04-29 PT PT11717917T patent/PT2563763E/pt unknown
- 2011-04-29 PH PH1/2012/502019A patent/PH12012502019A1/en unknown
- 2011-04-29 DK DK11717917.6T patent/DK2563763T3/en active
- 2011-04-29 SG SG2012076865A patent/SG184891A1/en unknown
- 2011-04-29 ES ES11717917.6T patent/ES2533075T3/es active Active
- 2011-04-29 JP JP2013508267A patent/JP5820874B2/ja active Active
- 2011-04-29 MY MYPI2012004708A patent/MY183769A/en unknown
- 2011-04-29 SI SI201130405T patent/SI2563763T1/sl unknown
-
2014
- 2014-09-15 US US14/486,139 patent/US9233948B2/en active Active
-
2015
- 2015-03-18 SM SM201500069T patent/SMT201500069B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12012502019A1 (en) | 2017-08-18 |
| SI2563763T1 (sl) | 2015-03-31 |
| WO2011137274A1 (en) | 2011-11-03 |
| PT2563763E (pt) | 2015-03-31 |
| AU2011245269A1 (en) | 2012-12-20 |
| SG184891A1 (en) | 2012-11-29 |
| US9233948B2 (en) | 2016-01-12 |
| ES2533075T3 (es) | 2015-04-07 |
| CN102971296A (zh) | 2013-03-13 |
| EP2563763A1 (en) | 2013-03-06 |
| RS53790B1 (sr) | 2015-06-30 |
| KR20130100237A (ko) | 2013-09-10 |
| US20130039989A1 (en) | 2013-02-14 |
| CN102971296B (zh) | 2015-11-25 |
| SMT201500069B (it) | 2015-05-05 |
| HK1179260A1 (en) | 2013-09-27 |
| EP2563763B1 (en) | 2014-12-31 |
| US8911785B2 (en) | 2014-12-16 |
| PL2563763T3 (pl) | 2015-06-30 |
| US20150065719A1 (en) | 2015-03-05 |
| HRP20150105T1 (hr) | 2015-03-13 |
| JP5820874B2 (ja) | 2015-11-24 |
| JP2013525455A (ja) | 2013-06-20 |
| DK2563763T3 (en) | 2015-04-07 |
| KR101897302B1 (ko) | 2018-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
| MD20140063A2 (ro) | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV | |
| BR112012007747B8 (pt) | compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos | |
| MY177344A (en) | Compounds and their methods of use | |
| NZ748345A (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
| MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
| AU2012284088A8 (en) | Heterocyclic compounds and uses thereof | |
| TN2013000362A1 (en) | Benzodioxane inhibitors of leukotriene production | |
| EA030383B9 (ru) | Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением | |
| MX363270B (es) | Composiciones y metodos para inhibir la polimerasa viral. | |
| TW201613885A (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
| CA2878796C (en) | Derivatives of pyridinone as inhibitors for tissue transglutaminase | |
| PH12015501088A1 (en) | Dimeric compounds | |
| EA201300946A1 (ru) | Асимметричные мочевины и их медицинское применение | |
| MY174239A (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| MY173636A (en) | Method of treating dengue fever | |
| PH12017500595A1 (en) | Aldosterone synthase inhibitors | |
| PH12012502019A1 (en) | Pharmaceutical compositions comprising n-(4-(2-amino -3-chloropyridin -4-yloxy) -3-fluorophenyl) -4-ethoxy-l- (4-fluorophenyl) -2-oxo-1,2- dihydropyridine-3-carboxamide | |
| MY166463A (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| MX2014014524A (es) | Composiciones que comprenden calcogenuros y metodos relacionados. | |
| WO2013192046A3 (en) | Substituted picolinamide kinase inhibitors | |
| GEP201706614B (en) | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process | |
| CY1116335T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν ν-(4(2-αμινο-3-χλωροπυριδιν-4-υλοξυ)-3-φθοροφαινυλ)-4-αιθοξυ-l-(4-φθοροφαινυλ)-2-οξο-1,2-διυδροπυριδιν-3-καρβοξαμιδιο | |
| MX2011012329A (es) | Nuevas sales farmaceuticamente aceptables de 4-(1h-imidazol-4-ilme til)piridina y sus usos terapeuticos. |